Cytek® Biosciences Introduces New 20-Color AML Panel
Cytek Biosciences (Nasdaq: CTKB) launched a new 20-Color Acute Myeloid Leukemia (AML) Panel, designed for efficient AML research and measurable residual disease (MRD) detection. This single-tube flow panel enhances operational efficiency by streamlining sample preparation, reducing reagent waste, and improving sensitivity. Utilizing Cytek’s Full Spectrum Profiling™ technology, it enables detailed analysis of normal and aberrant cells, offering critical support for drug discovery and clinical trials. The panel aims to aid researchers in developing life-saving therapies while conserving precious sample resources.
- Launch of a new 20-Color AML Panel enhances operational efficiency.
- Single-tube assay saves time and reduces labor costs in sample preparation.
- Improved assay sensitivity increases the potential for accurate research outcomes.
- Utilizes Full Spectrum Profiling technology for comprehensive cellular analysis.
- None.
Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection
FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel. A new single-tube flow panel for the development of AML therapies, this pre-optimized assay allows researchers to quickly and efficiently run AML analysis on any Cytek® Aurora or Northern Lights™ system equipped with violet, blue and red lasers.
Multiparametric flow cytometry assays are widely used in detecting and monitoring AML in drug discovery, translational research and clinical trials. Historically on conventional flow cytometers, markers used for assessing AML are typically split into multiple tubes due to the limitation of detection channels, forcing the use of redundant markers and greater sample volume. Cytek’s single-tube, 20-color panel for AML ends this wasteful practice, enhancing laboratory operational efficiency by saving time and labor for sample preparation and acquisition, as well as preserving precious samples and eliminating the use of redundant reagents. Additionally, pre-optimization eliminates the need for costly, labor-intensive panel design and optimization.
Cytek’s 20-Color AML Panel is an effective and sensitive flow cytometric approach for identifying and characterizing normal and aberrant cells, immunophenotyping, and evaluating measurable residual disease (MRD) in AML samples. The new panel unleashes the power of Cytek’s Full Spectrum Profiling™ (FSP™) technology – and is built on the company’s extensive experience pioneering and revolutionizing full spectrum flow cytometry to offer a more comprehensive understanding of the human immune system.
Key benefits include:
- Single-tube assay eliminates the use of redundant reagents
- Reduces time and labor in sample preparation and acquisition
- Provides more cellular information and improves assay sensitivity
- Preserves precious samples (especially for MRD tests that require a large amount of sample to be used)
“By providing total solutions for specific application areas such as MRD, we are giving researchers and scientists new leverage to jumpstart their discoveries and advance the development of life-saving therapies,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences.
For more information about Cytek’s 20-Color AML Panel, please visit: https://cytekbio.com/products/cytek-20-color-aml-panel-cfluor-reagent-kit-19c?variant=40563300433956.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. With the acquisition of DiaSorin’s Flow Cytometry & Imaging business unit in February 2023, Cytek added Amnis® imaging flow cytometers and Guava® flow cytometers to its solution lineup. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures. Please contact your local sales representatives for the status of local regulatory approval.
Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate Twitter account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek Biosciences’ product plans and strategies. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to market conditions; the ongoing COVID-19 pandemic; Cytek Biosciences’ dependence on certain sole and single source suppliers; competition; market acceptance of Cytek Biosciences’ current and potential products; Cytek Biosciences’ ability to manage the growth and complexity of its organization; Cytek Biosciences’ ability to maintain, protect and enhance its intellectual property; and Cytek Biosciences’ ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek Biosciences’ Annual Report on Form 10-K filed with the SEC on March 1, 2023 and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek Biosciences’ forward-looking statements. Although Cytek Biosciences believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek Biosciences as of the date hereof, and Cytek Biosciences disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek Biosciences’ views as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
What is the new product launched by Cytek Biosciences?
How does the 20-Color AML Panel benefit researchers?
What technology is used in the 20-Color AML Panel?
What does the 20-Color AML Panel analyze?
When was the 20-Color AML Panel launched?
